Pharmacokinetics/pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniae in mouse thigh and lung infection models

Journal of Antimicrobial Chemotherapy

Volumn 73, Issue 2, 2018, Pages 462-468

  Landersdorfer, Cornelia B ^a,b   Wang, Jiping ^a   Wirth, Veronika ^a   Chen, Ke ^a   Kaye, Keith S ^c   Tsuji, Brian T ^b,d   Li, Jian ^a   Nation, Roger L ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d Nys Centre of Excellence in Bioinformatics and Life Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; PLASMA PROTEIN; POLYMYXIN B; PROTEIN BINDING;

ANIMAL; BACTERIAL LOAD; CHEMISTRY; DISEASE MODEL; DRUG EFFECT; FEMALE; KLEBSIELLA INFECTION; KLEBSIELLA PNEUMONIAE; METABOLISM; MICROBIAL SENSITIVITY TEST; MOUSE; PLASMA; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL LOAD; BLOOD PROTEINS; DISEASE MODELS, ANIMAL; FEMALE; INJECTIONS, SUBCUTANEOUS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICE; MICROBIAL SENSITIVITY TESTS; PLASMA; POLYMYXIN B; PROTEIN BINDING;

EID: 85046030680     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkx409     Document Type: Article

References (36)

1. Nation RL, Velkov T, Li J. Colistin and polymyxin B: peas in a pod, or chalk and cheese? Clin Infect Dis 2014; 59: 88-94.
2. Sader HS, Rhomberg PR, Farrell DJ et al. Differences in potency and categorical agreement between colistin and polymyxin Bwhen testing 15, 377 clinical strains collectedworldwide. DiagnMicrobiol Infect Dis 2015; 83: 379-81.
3. Nation RL, Li J, Cars O et al. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis 2015; 15: 225-34.
4. Bergen PJ, Bulitta JB, Forrest A et al. Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model. Antimicrob Agents Chemother 2010; 54: 3783-9.
5. Cheah SE, Wang J, Nguyen VT et al. New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii inmouse thigh and lung infection models: smaller response in lung infection. J Antimicrob Chemother 2015; 70: 3291-7.
6. Hengzhuang W, Wu H, Ciofu O et al. In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection. Antimicrob Agents Chemother 2012; 56: 2683-90.
7. Lin YW, Zhou QT, Cheah SE et al. Pharmacokinetics/pharmacodynamics of pulmonary delivery of colistin against Pseudomonas aeruginosa in a mouse lung infection model. Antimicrob Agents Chemother 2017; 61: doi: 10.1128/AAC.02025-16.
8. Khan DD, Friberg LE, Nielsen EI. A pharmacokinetic/pharmacodynamic (PK/PD)model based on in vitro time-kill data predicts the in vivo PK/PD index of colistin. J Antimicrob Chemother 2016; 71: 1881-4.
9. TamVH, Schilling AN, Vo G et al. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005; 49: 3624-30.
10. Recommendations for MIC Determination of Colistin (Polymyxin E): As Recommended by the Joint CLSI-EUCAST Polymyxin Breakpoints Working Group 2016. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/General-documents/Recommendations-for-MIC-determination-of- colistin-March-2016.pdf.
11. Cheah SE, Bulitta JB, Li J et al. Development and validation of a liquid chromatography-mass spectrometry assay for polymyxin B in bacterial growth media. J Pharm Biomed Anal 2014; 92: 177-82.
12. Bauer RJ, Guzy S, Ng C. A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples. AAPS J 2007; 9: E60-83.
13. Bulitta JB, Landersdorfer CB. Performance and robustness of the Monte Carlo importance sampling algorithm using parallelized S-ADAPT for basic and complex mechanisticmodels. AAPS J 2011; 13: 212-26.
14. Bulitta JB, Bingolbali A, Shin BS et al. Development of a new pre- and post-processing tool (SADAPT-TRAN) for nonlinearmixed-effects modeling in S-ADAPT. AAPS J 2011; 13: 201-11.
15. He J, Gao S, Hu M et al. A validated ultra-performance liquid chromatography-tandemmass spectrometry method for the quantification of polymyxin B inmouse serum and epithelial lining fluid: application to pharmacokinetic studies. J Antimicrob Chemother 2013; 68: 1104-10.
16. Bowers DR, Cao H, Zhou J et al. Assessment of minocycline and polymyxin B combination against Acinetobacter baumannii. Antimicrob Agents Chemother 2015; 59: 2720.
17. Berkhout J, Melchers MJ, van Mil AC et al. Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infectedmice. Antimicrob Agents Chemother 2015; 59: 2299-304.
18. Sandri AM, Landersdorfer CB, Jacob J et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 2013; 57: 524-31.
19. Nation RL, Garonzik SM, Li J et al. Updated US and European dose recommendations for intravenous colistin: how do they perform? Clin Infect Dis 2016; 62: 552-8.
20. Utley L, Coleman S. In-vitro ADME Properties of SPR741 Support Progression into Clinical Development. ASM Microbe 2017, New Orleans. http://www.abstractsonline.com/pp8/#!/4358/presentation/7135. American Society for Microbiology, Washington, DC, USA, 2017.
21. Lepak AJ, Andes DR. In vivo pharmacodynamic target assessment of delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a murine lung infection model. Antimicrob Agents Chemother 2016; 60: 4764-9.
22. Lepak AJ, Zhao M, Marchillo K et al. In vivo pharmacodynamic evaluation of omadacycline (PTK 0796) against Streptococcus pneumoniae in themurine pneumoniamodel. Antimicrob Agents Chemother 2017; 61: pii=e02368-16.
23. Bulik CC, Okusanya OO, Lakota EA et al. Pharmacokinetic-pharmacodynamic evaluation of gepotidacin against Gram-positive organisms using data from murine infection models. Antimicrob Agents Chemother 2017; 61: pii=e00115-6.
24. Nation RL, Garonzik SM, Thamlikitkul V et al. Dosing guidance for intravenous colistin in critically ill patients. Clin Infect Dis 2017; 64: 565-71.
25. Llobet E, Tomas JM, Bengoechea JA. Capsule polysaccharide is a bacterial decoy for antimicrobial peptides. Microbiology 2008; 154: 3877-86.
26. Velkov T, Deris ZZ, Huang JX et al. Surface changes and polymyxin interactions with a resistant strain of Klebsiella pneumoniae. Innate Immun 2014; 20: 350-63.
27. Kaye KS, Pogue JM, Tran TB et al. Agents of last resort: polymyxin resistance. Infect Dis Clin NorthAm2016; 30: 391-414.
28. Lu Q, Girardi C, ZhangMet al.Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa. Intensive Care Med 2010; 36: 1147-55.
29. Yapa SWS, Li J, Porter CJ et al. Population pharmacokinetics of colistin methanesulfonate in rats: achieving sustained lung concentrations of colistin for targeting respiratory infections. Antimicrob Agents Chemother 2013; 57: 5087-95.
30. Marchand S, Gobin P, Brillault J et al. Aerosol therapy with colistin methanesulfonate: a biopharmaceutical issue illustrated in rats. Antimicrob Agents Chemother 2010; 54: 3702-7.
31. Gontijo AV, Gregoire N, Lamarche I et al. Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 2. Colistin. Antimicrob Agents Chemother 2014; 58: 3950-6.
32. Athanassa ZE, Markantonis SL, Fousteri MZ et al. Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients. IntensiveCareMed2012; 38: 1779-86.
33. Yapa SWS, Li J, Patel K et al. Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration. Antimicrob Agents Chemother 2014; 58: 2570-9.
34. BoissonM, JacobsM, Gregoire N et al. Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients. Antimicrob Agents Chemother 2014; 58: 7331-9.
35. Gu WJ, Wang F, Tang L et al. Colistin for the treatment of ventilatorassociated pneumonia caused by multidrug-resistant Gram-negative bacteria: a systematic review and meta-analysis. Int J Antimicrob Agents 2014; 44: 477-85.
36. Valachis A, Samonis G, Kofteridis DP. The role of aerosolized colistin in the treatment of ventilator-associated pneumonia a systematic review and metaanalysis. Crit CareMed2015; 43: 527-33.